Company research
CV Sciences, Inc.
CIK 1510964Updated Sep 24, 2026
SecurityCVSI · OTC · equity
Name history
CannaVEST Corp. · through Jan 4, 2016Foreclosure Solutions, Inc. · through Nov 30, 2012
CVSI price & chart
Loading TradingView…
OTC:CVSI on TradingView ↗About the company
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces non-cannabinoid supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that…
In the news
No coverage from other publishers is available.
Recent filings
4 filing
3 filing
10-Q filing
Results of Operations and Financial Condition · Other Events
Items 2.02, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 6,962,000Source | 7,927,000Source | 9,200,000Source | 12,736,000Source |
| Property, Plant and Equipment, NetUSD | 344,000Source | 399,000Source | 379,000Source | 575,000Source |
| GoodwillUSD | 1,015,000Source | 971,000Source | 342,000Source | 0Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 76,000Source | 93,000Source | 78,000Source | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 611,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 402,000Source | 522,000Source | 431,000Source | 766,000Source |
| Inventory, NetUSD | 4,087,000Source | 4,897,000Source | 5,655,000Source | 6,563,000Source |
| Assets, CurrentUSD | 5,133,000Source | 6,243,000Source | 7,938,000Source | 11,130,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 366,000Source | 370,000Source | 535,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 347,000Source | 94,000Source | 167,000Source | 275,000Source |
| Other Assets, NoncurrentUSD | 47,000Source | 127,000Source | 296,000Source | 505,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 5,494,000Source | 6,132,000Source | 6,297,000Source | 13,513,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | — | 0Source |
| Common Stock, Value, IssuedUSD | 18,000Source | 18,000Source | 16,000Source | 15,000Source |
| Additional Paid in CapitalUSD | 89,330,000Source | 88,773,000Source | 87,464,000Source | 86,897,000Source |
| Retained Earnings (Accumulated Deficit)USD | -87,939,000Source | -86,981,000Source | -84,587,000Source | -87,689,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 59,000Source | -15,000Source | 10,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 1,468,000Source | 1,795,000Source | 2,903,000Source | -777,000Source |
| Liabilities and EquityUSD | 6,962,000Source | 7,927,000Source | 9,200,000Source | 12,736,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,000,000Source | 6,109,000Source | 6,115,000Source | 13,314,000Source |
| Operating Lease, Liability, CurrentUSD | 247,000Source | 83,000Source | 130,000Source | 117,000Source |
| Accounts Payable, CurrentUSD | 1,044,000Source | 1,925,000Source | 2,309,000Source | 2,284,000Source |
| Operating Lease, Liability, NoncurrentUSD | 100,000Source | 19,000Source | 58,000Source | 188,000Source |
| Deferred Income Tax Liabilities, NetUSD | 7,000Source | 4,000Source | 19,000Source | 11,000Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 105,000Source | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,447,000Source | 3,424,000Source | 3,422,000Source | 9,690,000Source |
| Long-term DebtUSD | 1,649,000Source | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 1,262,000Source | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 387,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 192,000Source | 334,000Source | 235,000Source | 992,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 497,000Source | 258,000Source | 218,000Source | 1,009,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -124,000Source | 84,000Source | -352,000Source | -1,065,000Source |
| Increase (Decrease) in InventoriesUSD | -827,000Source | -803,000Source | -1,042,000Source | -2,061,000Source |
| Deferred Income Tax Expense (Benefit)USD | 3,000Source | -15,000Source | -14,000Source | -51,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -407,000Source | -861,000Source | 2,253,000Source | -1,885,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 0Source | 10,000Source | 156,000Source | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -109,000Source | -28,000Source | -156,000Source | 0Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 109,000Source | 18,000Source | — | 0Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 337,000Source | 32,000Source | -1,391,000Source | 1,121,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -176,000Source | -863,000Source | 706,000Source | -764,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 278,000Source | 454,000Source | 1,317,000Source | 611,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 6,000Source | 8,000Source | 7,000Source | 6,000Source |
| Income Taxes Paid, NetUSD | 8,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 3,000Source | -6,000Source | — | — |
| Additional Financial Items | ||||
| AmortizationUSD | — | — | — | 0Source |
| Amortization of Intangible AssetsUSD | 24,000Source | 21,000Source | 1,000Source | — |
| DepreciationUSD | 200,000Source | 300,000Source | 200,000Source | 1,000,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | -150,000Source |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | 38,000Source | — | 0Source | 127,000Source |
| General and Administrative ExpenseUSD | 3,153,000Source | 3,986,000Source | — | 12,090,000Source |
| GoodwillUSD | 1,015,000Source | 971,000Source | 342,000Source | 0Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | 251,000Source | 1,234,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 251,000Source | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | 0Source | — | — |
| Income Tax Expense (Benefit)USD | 9,000Source | -8,000Source | -6,000Source | -47,000Source |
| InterestExpenseNonoperatingUSD | 517,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -958,000Source | -2,394,000Source | 3,102,000Source | -8,214,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -2,394,000Source | 3,102,000Source | -9,134,000Source |
| Operating ExpensesUSD | — | — | — | 12,397,000Source |
| Other Nonoperating Income (Expense)USD | -479,000Source | -212,000Source | -264,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 13,789,000Source | 15,705,000Source | 16,004,000Source | 16,205,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 7,622,000Source | 9,240,000Source | 9,745,000Source | — |
| Operating Income (Loss)USD | -470,000Source | -2,190,000Source | 3,360,000Source | -6,847,000Source |
| Other Nonoperating Income (Expense)USD | -479,000Source | -212,000Source | -264,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -949,000Source | -2,402,000Source | 3,096,000Source | -8,261,000Source |
| Income Tax Expense (Benefit)USD | 9,000Source | -8,000Source | -6,000Source | -47,000Source |
| Net Income (Loss) Attributable to ParentUSD | -958,000Source | -2,394,000Source | 3,102,000Source | -8,214,000Source |
| Earnings Per Share, BasicUSD per share | -0.01Source | -0.01Source | 0.02Source | -0.07Source |
| Earnings Per Share, DilutedUSD per share | -0.01Source | -0.01Source | 0.02Source | -0.07Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 184,264,000Source | 175,585,000Source | 153,954,000Source | 138,034,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 184,264,000Source | 175,585,000Source | 153,955,000Source | 138,034,000Source |
| Interest Expense (non-operating)USD | 517,000Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 24,000Source | 21,000Source | 1,000Source | — |
| Current Income Tax Expense (Benefit)USD | 6,000Source | 7,000Source | 8,000Source | 4,000Source |
| General and Administrative ExpenseUSD | 3,153,000Source | 3,986,000Source | — | 12,090,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 6,752,000Source | 7,168,000Source | 7,085,000Source | 5,550,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -582,000Source | -2,141,000Source | 3,114,000Source | — |
| Interest Expense, DebtUSD | — | — | — | 600,000Source |
| Interest Income (Expense), NetUSD | — | — | — | -1,541,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -2,394,000Source | 3,102,000Source | -9,134,000Source |
| Operating ExpensesUSD | — | — | — | 12,397,000Source |
| Research and Development ExpenseUSD | 122,000Source | 118,000Source | 151,000Source | 307,000Source |
| Selling ExpenseUSD | 2,803,000Source | 3,166,000Source | — | — |
Filing attachments
cvsi-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2026. Second Quarter 2026 an…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results San Diego, CA - May 14, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended March 31, 2026. First Quarter 2026 and Re…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2026-03-26
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results San Diego, CA - March 26, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the year and quarter ended December 31, 2025. Fiscal 2025, …
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2026-03-10
EX-99.1 6 cvsi-ex99_1.htm EX-99.1 EX-99.1 March 10, 2026 CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in proven, science-backed natural ingredients and products, today announced that it has modified its existing outstanding notes to i…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2025-11-13
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter 2025 Financial Results San Diego, CA - November 13, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2025. Third Quarter 2025 a…
Read attachment ↗cvsi-ex99_1.htm · 8-K · 2025-08-13
EX-99.1 2 cvsi-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter 2025 Financial Results San Diego, CA - August 13, 2025 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended June 30, 2025. Second Quarter 2025 and Re…
Read attachment ↗